Angela K. Deem

Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Andrea Viale, Piergiorgio Pettazzoni, Costas A. Lyssiotis, Haoqiang Ying et autres

us, it (code pays fourni par la source)

Abstract 3243: Investigating the value of testing for actionable alterations and circulating tumor DNA in breast and colorectal cancers

Gargi D. Basu, Nick Johnson, Angela K. Deem, Judith Frederick et autres

Abstract Tumor molecular profiling may reveal distinct biological behaviors by identifying actionable alterations (AAs), informing precision oncology. However, the effect of molecular characteristics on ctDNA detection and monitoring is not well studied. Here, we evaluated patients with breast cancer (BC; all subtypes) …

us (code pays fourni par la source)

Characterization of ESR1 alterations in patients with breast and gynecologic cancers

Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres

BACKGROUND: ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. METHODS: A retrospective study …

us (code pays fourni par la source)

Characterization of ESR1 alterations in patients with breast and gynecologic cancers

Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres

Abstract Background ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. Methods A retrospective …

us (code pays fourni par la source)

Additional file 1 of Characterization of ESR1 alterations in patients with breast and gynecologic cancers

Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres

Supplementary material 1

us (code pays fourni par la source)

Characterization of ESR1 alterations in patients with breast and gynecologic cancers

Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres

Abstract Background ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials. Methods A retrospective …

us (code pays fourni par la source)

Additional file 1 of Characterization of ESR1 alterations in patients with breast and gynecologic cancers

Gargi D. Basu, Paige Innis, Angela K. Deem, Arthur Starodynov et autres

Supplementary material 1

us (code pays fourni par la source)

Comprehensive genomic profiling of over 10,000 advanced solid tumors

Jean-Paul De La O, Jess Hoag, Angela K. Deem, Min Wang et autres

// Jean-Paul De La O 1 , Jess R. Hoag 1 , Angela K. Deem 1 , Min Wang 1 , Arthur Starodynov 1 , Sameer S. Udhane 1 , Janine R. LoBello 1 , Nishitha Therala 1 , David W. Hall …

us (code pays fourni par la source)

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

Madelaine Skolastika Theardy, Mitsunobu Takeda, Alexey V. Sorokin, Shuaitong Chen et autres

The therapeutic benefit of recently developed mutant KRAS (KRAS∗) inhibitors remains limited by the rapid onset of resistance. Here, we aim to delineate mechanisms underlying acquired resistance and identify actionable targets for overcoming this clinical challenge. Previously, we identified syndecan-1 (SDC1) as …

us, jp (code pays fourni par la source)

Abstract P3-03-30: Molecular landscape of breast cancer in pre- and postmenopausal women

Sameer S. Udhane, Pawan Noel, Fadel Alyaqoub, Ariane Kemkes et autres

Abstract Background: Breast cancer (BC) in younger women is often more aggressive and diagnosed at a later stage. The choice of endocrine therapy (ET) for women with hormone-receptor positive (HR+) BC varies based on whether she is premenopausal (preM) or postmenopausal (postM): …

Comparison of mutational landscape in primary and metastatic pancreatic tumors.

Jean–Paul De La O, Jess Hoag, Gargi D. Basu, Arthur Starodynov et autres

781 Background: Genomic profiling has brought to the forefront the clinical relevance of intratumoral heterogeneity. Oncogenic KRAS mutation is the most common driver event in pancreatic ductal adenocarcinoma (PDAC), but little is known about how KRAS alteration may cooperate with other genetic …

us (code pays fourni par la source)

WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer

Francesca Citron, I-Lin Ho, Chiara Balestrieri, Zhaoliang Liu et autres

It is unclear how cells counteract the potentially harmful effects of uncoordinated DNA replication in the context of oncogenic stress. Here, we identify the WRAD (WDR5/RBBP5/ASH2L/DPY30) core as a modulator of DNA replication in pancreatic ductal adenocarcinoma (PDAC) models. Molecular analyses demonstrated …

us, it, ca (code pays fourni par la source)